The number of sequenced genomes grows exponentially. According to forecasts, in 2016 approximately 25 million genomes will be sequenced. The incorporation of whole-genome and whole-exome sequencing into clinical practice will undoubtedly change the way genetic counselors and other clinicians approach genetic testing.
Human genome sequencing for clinical purposes is associated with detailed and precise Big Data analysis. Initial raw data includes approximately 200GB of genetic data per patient. This is analyzed using either desktop applications or SaaS. Current solution methods require some special knowledge and do not provide medical reports. This greatly delays total turnaround time and decreases the sequencing capacity of service providers, as modern genome analyzers allow generation of raw data for one human genome in only 6 hours. iBinom offers a solution for this.
Our iBinom solution is a Simple, Fast & Affordable service for genomic data interpretation:
1. Simple and user-friendly interface designed for physicians and geneticists. No special knowledge is required. Medical report may be downloaded in 1 click.
2. Amazon and Yandex IaaS services paired with our fast proprietary algorithms of data analysis allows single human genome analysis in only 30 minutes.
3. Flexible and affordable prices for human genome analysis with a medical report.
We use a SaaS business model — our customers pay a fixed price per one analysis and a monthly fee for storage. We sell our solution to three groups of customers: medical centers, research centers, and sequence providers. According to the Transparency Market Research (2013), the global bioinformatics market will reach $8.3 billion in 2014.
Andrey Afanasyev, CEO. Has held leadership positions in three high technology start-up companies focused in the medical applications. In these companies his role included team development, executive team management, marketing and sales for complex technologies. His projects include medical devices, new radiopharmaceuticals and immunotherapeutic cancer treatment. He holds a M.S. in Physics with a focus on Big Data analysis from experiments. Additionally, he was educated in the field of entrepreneurship from Moscow State University.
Valery Ilinsky, co-founder. Accomplished molecular biologist. Valery's professional background includes research on genome wide gene-gene interaction networks at the Moscow State University, genetic maps at the Institute for General Genetics, cancer-associated gene analysis in colorectal carcinomas at the University of Zurich and HIV genome functional analysis at the George Washington University. His areas of scientific expertise include high-throughput screening, genome annotation, gene expression analysis, and next generation sequencing technologies. Valery holds a M.S. in Biochemistry with a focus on eukaryote genome analysis from Moscow State University.
Alexey Brodsky, CTO. At his previous work in Yandex (the largest search engine in Russia) he leads Analytical Instruments Development Group and Data Analysis Service for 3 years. He has an extensive background in Big Data analysis and Data Mining. Also, he implements change points detection and forecasting system for main Yandex business processes. He is an expert in machine learning and information retrieval. Alexey holds M.S. in Mathematical Cybernetics from Yaroslavl Demidov State University and Ph.D. in Discrete Mathematics from Lobachevsky State University. To bridge the gap between academic research and applied technology he received his second M.S. in Data Analysis from Yandex Data Analysis School.
We also hired 5 experienced programmers with a background in bioinformatics, Big Data analysis, and algorithms. By the end of 2013, we plan to hire 3 more programmers, as well as an experienced sales manager.
Andrey Afanasyev, CEO
+7 (926) 369-34-26